In conclusion, monoclonal anti-CD20+ B cells antibody therapy (rituximab) combined with MTX, beside a significant clinical improvement, diminished serum MMP-1, MMP-3, MMP-9 and TIMP-1 levels in active RA patients refractory to anti-TNF therapy. Here, MMP1 is linked to rheumatoid arthritis.